Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prosena Therapeutics

- PMLiVE

GSK set for 2017 European rollout of med device asthma app

Updated version of the MyAsthma iPhone app is firm's first Class 1 med device

- PMLiVE

GSK starts late-stage trials of daprodustat

Drug hopes to treat anaemia caused by chronic kidney disease

- PMLiVE

Pharma ramps up its use of Instagram

GSK became the latest firm to join the social network, signing up last month

- PMLiVE

GSK and J&J file sirukumab for rheumatoid arthritis in EU

If approved it will compete with Roche blockbuster Actemra

- PMLiVE

GSK launches first pharma trial powered by Apple’s ResearchKit

Will use an iPhone app built using the software for a real-world study

- PMLiVE

GSK signs up for the ‘dawn of cognitive advertising’

Its consumer health arm is among the first to use new IBM offering Watson Ads

Biomarin

BioMarin gives up on muscular dystrophy drug

Makes ‘difficult but necessary’ decision to abandon exon-skipping therapy Kyndrisa

- PMLiVE

GSK’s chief executive Sir Andrew Witty to retire next year

The announcement follows months of speculation about his position

- PMLiVE

GSK appoints rare diseases research head

Birgitte Volck moves to the company from Swedish Ophan Biovitrum

- PMLiVE

GSK plans sirukumab filing in rheumatoid arthritis next year

Says phase III trials showed 'no unexpected safety findings'

- PMLiVE

GSK’s severe asthma therapy Nucala gets EU nod

Becomes the first IL-5 inhibitor to be approved in the EU

- PMLiVE

GSK bags FDA approval for severe asthma drug Nucala

Drug to be launched as soon as possible

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links